<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute myeloid leukemia in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute myeloid leukemia in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute myeloid leukemia in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine Tarlock, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd M Cooper, DO</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H449859826"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute leukemia is the most common cancer in children, and it corresponds to one-third of all childhood malignancies. Acute myeloid leukemia (AML) accounts for approximately 15 percent of childhood leukemia, while acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) corresponds to 80 percent of pediatric acute leukemia. </p><p>Treatment in clinical trials, risk stratification, intensification of therapy, and improved supportive care have contributed to improved survival for children and adolescents with AML, but outcomes remain inferior to those with ALL/LBL. </p><p>This topic reviews AML in children and adolescents. </p><p>Treatment of childhood ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H449859839"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The most common presenting symptoms of AML in children and adolescents are findings associated with the leukemic burden, associated cytopenias, or disease complications. The clinical presentation of AML may be indistinguishable from that of acute lymphoblastic leukemia/lymphoblastic lymphoma.</p><p>Patients can present with fever, malaise, musculoskeletal pains, lymphadenopathy, or hepatosplenomegaly. They may have clinical manifestations of cytopenias, including anemia (eg, pallor, fatigue, dyspnea), thrombocytopenia (eg, unusual bleeding or bruising), and/or neutropenia (eg, infection). </p><p>In some children, AML is first suspected because of laboratory abnormalities, such as circulating myeloblasts, electrolyte derangements, or liver dysfunction.</p><p>Less often, children present with symptoms related to complications of AML, such as involvement of the central nervous system (eg, headache, lethargy, mental status changes, cranial nerve palsies) or other extramedullary sites. Some children have respiratory or neurologic distress due to leukostasis (extreme levels of circulating myeloblasts). Disseminated intravascular coagulation can be present, especially in patients with acute promyelocytic leukemia. </p><p class="headingAnchor" id="H1599220807"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation of AML in children and adolescents includes history and physical examination, laboratory tests, bone marrow examination, and other clinical studies. </p><p class="headingAnchor" id="H3674269669"><span class="h2">Clinical/laboratory testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – History should evaluate the child for symptoms, described above, related to tumor burden, cytopenias, and extramedullary involvement. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">Family history should determine if relatives have conditions consistent with a familial/inherited basis for the leukemia. Examples include other leukemias, myelodysplastic syndromes/neoplasms (MDS), or multiple cancers; suspicious abnormalities of hair, skin, nails, or organ dysfunction (eg, lung or liver); deafness; and short stature, as discussed separately. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p></p><p class="bulletIndent1">Physical examination should evaluate the child for hepatosplenomegaly, bleeding/bruising, findings that may reflect an inherited/familial condition, or involvement of the central nervous system (CNS) or other extramedullary sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Blood counts and coagulation tests:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count with leukocyte differential count</p><p class="bulletIndent3"><span class="glyph">-</span>Prothrombin time, activated partial thromboplastin time, fibrinogen </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistries</strong> – Electrolytes, glucose, kidney function, liver function tests, including lactate dehydrogenase, calcium, magnesium, phosphorus, uric acid, albumin </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other clinical studies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lumbar puncture </strong>– All children with suspected AML should have a lumbar puncture (LP) soon after diagnosis to examine cerebrospinal fluid, which should be analyzed by cell count, protein, glucose, and cytology (examination of stained cytospin slides). (See  <a class="medical medical_review" href="/d/html/6325.html" rel="external">"Lumbar puncture in children"</a>.)</p><p></p><p class="bulletIndent2">Leukemic involvement of the CNS is generally defined as &gt;5 x 10<sup>6 </sup>leukocytes/L cerebrospinal fluid including blasts, in a nonbloody specimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Imaging is performed, as clinically indicated, to assess leukemic involvement of extramedullary sites. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Central nervous system </strong>– For children with unexplained neurologic abnormalities, computed tomography (CT) and/or magnetic resonance imaging (MRI) should be performed to assess the patient for mass lesions or meningeal involvement. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other extramedullary sites</strong> – Suspected extramedullary involvement by AML should be evaluated by CT, positron emission tomography, and/or MRI, as clinically indicated.</p><p></p><p class="headingAnchor" id="H2415501850"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Bone marrow, peripheral blood, and suspected sites of extramedullary involvement should be evaluated for blasts. Analysis includes morphology, immunophenotype, cytogenetics, and molecular features, which are essential for distinguishing AML from ALL and other disorders.</p><p>Characteristic pathologic findings in childhood AML include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphology</strong> – Myeloblasts are immature cells with large nuclei, usually with prominent nucleoli, and a variable amount of pale blue cytoplasm. Myeloid blasts typically have more abundant cytoplasm than lymphoid blasts and may have granules or Auer rods  (<a class="graphic graphic_picture graphicRef78291" href="/d/graphic/78291.html" rel="external">picture 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – The immunophenotype of the blasts is determined by flow cytometry and/or immunohistochemistry. </p><p></p><p class="bulletIndent1">AML blasts express myeloid markers, such as CD11b, CD34, CD33, CD45, CD64, CD65, CD117, myeloperoxidase (MPO), and lysozyme. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetics</strong> – Cytogenetic abnormalities are found in three-quarters of pediatric AML cases [<a href="#rid1">1</a>]. Many of these abnormalities have prognostic significance, as discussed below. (See <a class="local">'Cytogenetics'</a> below.)</p><p></p><p class="bulletIndent1">Although many cytogenetic abnormalities associated with pediatric AML are detected by conventional karyotype analysis, some require fluorescence in situ hybridization (FISH) or molecular techniques for detection. </p><p></p><p class="bulletIndent1">In addition to conventional karyotyping, FISH should evaluate the specimen for t(8;21), inv(16), t(15;17), and 11q23 translocations. (See  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities", section on 'Recurrent translocations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutation analysis</strong> –<em> </em>Pediatric AML is genetically heterogeneous, and the molecular profiles differ from those of adult AML. Certain mutations or genetic profiles have prognostic or therapeutic implications, as discussed below. (See <a class="local">'Molecular features'</a> below.)</p><p></p><p class="bulletIndent1">Deoxyribonucleic acid (DNA) sequencing and/or polymerase chain reaction (PCR) should be used to identify mutations of<em> NPM1</em>,<em> CEBPA</em>,<em> FLT3</em>,<em> KIT</em>, <em>WT1</em>, and/or cryptic fusions that are not detected by conventional cytogenetics [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/d/html/4502.html" rel="external">"Acute myeloid leukemia: Molecular genetics", section on 'Gene mutations'</a>.)</p><p></p><p class="headingAnchor" id="H1127751908"><span class="h1">DIAGNOSIS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>AML should be considered in a child or adolescent with unexplained cytopenias or associated symptoms, organomegaly, or blasts in peripheral blood. (See <a class="local">'Clinical presentation'</a> above.)</p><p class="headingAnchor" id="H2842962932"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Diagnosis of AML requires pathologic confirmation in bone marrow, with or without analysis of blood and/or sites of extramedullary involvement. </p><p>Diagnosis is based on morphology (microscopy) and immunophenotyping that reveal the myeloid lineage of blasts, along with cytogenetic and molecular analysis. Details of the diagnostic criteria for AML are presented separately. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Diagnosis'</a>.)</p><p>One of the following systems should be used to diagnose and classify AML:</p><p class="bulletIndent1"><span class="glyph">●</span>International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 5<sup>th</sup> edition of the World Health Organization (WHO5) of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms [<a href="#rid5">5</a>]</p><p></p><p>Both ICC and WHO5 classify hematopoietic neoplasms by integrating morphology (eg, cytology, histology, tissue architecture) and cellular lineage (by immunophenotype) with cytogenetic and molecular features. Use of either ICC or WHO5 is acceptable and should replace outdated classification systems, such as the FAB (French-American-British) classification system [<a href="#rid6">6</a>] or the revised 4<sup>th</sup> edition of the WHO classification system [<a href="#rid7">7</a>]. Details of the ICC and WHO5 classification systems are presented separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>Recognition of inherited/familial AML has important implications for management. Familial AML is demonstrated by personal and family history and genetic testing of the blasts and nonhematopoietic tissue to demonstrate the presence of an implicated gene variant/mutation in the germline. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H3568908058"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>AML must be distinguished from other types of leukemia and hematologic malignancies with blood/marrow involvement and from other conditions associated with cytopenias and/or circulating immature cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute lymphoblastic leukemia </strong>– Acute lymphoblastic leukemia (ALL) manifests similar clinical findings, but it is considerably more common than AML in children.</p><p></p><p class="bulletIndent1">Clinical findings are like those of AML, but ALL is more likely to present with extramedullary disease, such as a mediastinal mass. ALL blasts are generally smaller, have less conspicuous nucleoli, less cytoplasm, and lack intracytoplasmic granules and Auer rods. </p><p></p><p class="bulletIndent1">Immunophenotyping (eg, using flow cytometry) is essential for distinguishing the lymphoid blasts of ALL from the myeloid blasts of AML. Diagnosis of ALL in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other acute leukemias</strong> – A variety of childhood leukemias share clinical or morphologic similarities with AML. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed phenotype acute leukemia and acute undifferentiated leukemia are distinguished from AML by immunophenotype, as discussed separately. (See  <a class="medical medical_review" href="/d/html/116801.html" rel="external">"Mixed phenotype acute leukemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Juvenile myelomonocytic leukemia can present with organomegaly, but the malignant cells are not as immature and exhibit features of the monocytic lineage. (See  <a class="medical medical_review" href="/d/html/96034.html" rel="external">"Juvenile myelomonocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic myeloid leukemia</strong> – Accelerated phase or blast crisis of chronic myeloid leukemia (CML) typically manifests splenomegaly and/or constitutional symptoms, with an expanded population of circulating myeloid cells at various stages of differentiation. However, malignant cells of CML exhibit the characteristic t(9;22) chromosomal rearrangement (Philadelphia chromosome) and <em>BCR::ABL1</em> rearrangement, which distinguish them from AML blasts. (See  <a class="medical medical_review" href="/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myelodysplastic syndromes/neoplasms</strong> – Myelodysplastic syndromes/neoplasms (MDS) and AML are considered by many experts to be components of a spectrum of myeloid malignancies with related clinical features and certain aspects of natural history. MDS may present with cytopenias with circulating myeloid cells with aberrant morphology, including myeloblasts. MDS is distinguished from AML by fewer blasts in blood and marrow and by genetic abnormalities that differ from, but may overlap with, findings of AML.</p><p></p><p class="bulletIndent1">For cases with 10 to 20 percent myeloid blasts, the ICC does not distinguish between MDS and AML; such cases are labeled MDS/AML [<a href="#rid4">4</a>]. The WHO5 describes such cases as MDS with increased blasts [<a href="#rid5">5</a>]. Details of diagnosis and classification of MDS and AML are discussed separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myeloid neoplasms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukemoid reaction</strong> – A leukemoid reaction describes a high leukocyte count (eg, ≥50,000/microL) with neutrophilia and prominent left shift, usually in response to infection. However, myeloblasts and other very immature cells are scant or absent, and a leukemoid reaction can be distinguished by morphology. Bone marrow examination and/or cytogenetic testing is rarely needed to distinguish a leukemoid reaction from AML.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aplastic anemia</strong> – Aplastic anemia is a bone marrow failure state that presents with variable levels of pancytopenia and related symptoms. Aplastic anemia can be caused by drugs, infections, inherited conditions, and acquired/autoimmune damage to hematopoietic stem and progenitor cells. Bone marrow examination demonstrates profound hypoplasia of hematopoietic elements, and the marrow space is composed primarily of fat cells and marrow stroma. (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Evaluation and diagnosis of various forms of familial/inherited aplastic anemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a> and  <a class="medical medical_review" href="/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a> and  <a class="medical medical_review" href="/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.) </p><p></p><p>For children with Down syndrome (DS)/trisomy 21, it is important to distinguish transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with DS (ML-DS) from AML. TAM and ML-DS have very different natural histories and require management that is distinct from that of AML. (See  <a class="medical medical_review" href="/d/html/16914.html" rel="external">"Transient abnormal myelopoiesis (TAM) of Down syndrome (DS)"</a> and  <a class="medical medical_review" href="/d/html/139448.html" rel="external">"Myeloid leukemia associated with Down syndrome (ML-DS)"</a>.)</p><p class="headingAnchor" id="H3769250599"><span class="h2">Classification</span><span class="headingEndMark"> — </span>Cases of pediatric AML should be classified using either the ICC or the WHO5 system. Both systems assign AML subtypes according to morphologic, cytogenetic, and molecular features. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defining genetic abnormalities</strong> – ICC and WHO5 apply similar diagnostic criteria and labels for cases of AML with defining cytogenetic and molecular findings. </p><p></p><p class="bulletIndent1">Details of classification of AML subtypes with defining genetic abnormalities are presented separately. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification", section on 'AML with defining genetic abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cases of AML</strong> – For cases without AML-defining genetic abnormalities, ICC and WHO5 differ in the labels, diagnostic criteria, and assignment to disease categories. Differences between ICC and WHO5 that affect classification of pediatric AML include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>AML without a defining genetic abnormality</strong> – ICC defines many cases without defining genetic abnormalities as AML, not otherwise specified [<a href="#rid4">4</a>], while WHO5 categorizes them according to the degree of blast differentiation [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>AML associated with germline or inherited gene variants</strong> – AML associated with germline or inherited gene variants is described differently: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>International Consensus Classification</strong> – Cases of AML in association with a germline predisposition constitute a separate category, Hematologic neoplasms with germline predisposition; cases are further defined according to association with abnormalities in multiple organ systems, a constitutional platelet disorder, or no abnormalities in multiple organ systems.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>The 5</strong><strong><sup>th</sup></strong><strong> edition of the World Health Organization</strong> – Cases of AML in association with a germline predisposition are included in the category, Secondary myeloid neoplasms, which also includes therapy-related AML. Cases are assigned subtypes according to associated findings, as described with ICC classification above.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy-related AML</strong> – For AML that arises in a patient with prior exposure to cytotoxic agents, ionizing radiation, or immune interventions, "Therapy-related" is added as a qualifier following the diagnosis of AML in ICC. In WHO5, such cases are included in a category of Secondary myeloid neoplasms (which also includes AML in association with a germline predisposition).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myeloid sarcoma</strong> – This is a distinct subtype of AML in the ICC system, whereas it is described as a tissue-based manifestation of AML in WHO5. </p><p></p><p>Other details of differences between the ICC and WHO5 classification systems are presented separately. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification", section on 'Other subtypes'</a>.)</p><p class="headingAnchor" id="H449859894"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Prognosis in pediatric AML is informed by cytogenetic and molecular features of the blasts. For children whose AML has no prognostically important genetic features, outcomes are associated with the response to induction therapy. These prognostic features are important components of risk stratification for treatment of pediatric AML, as discussed below. (See <a class="local">'Risk stratification'</a> below.)</p><p class="headingAnchor" id="H449859901"><span class="h2">Cytogenetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable</strong> – AML with favorable cytogenetics accounts for approximately 20 to 30 percent of pediatric AML. Favorable cytogenetic features are: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(8;21)(q22;q22); <em>RUNX1::RUNX1T1</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Core-binding factor AML: inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB::MYH11</em></p><p></p><p class="bulletIndent1">Treatment on contemporary protocols with chemotherapy alone results in approximately 80 percent long-term overall survival (OS) and 70 percent relapse-free survival (RFS) [<a href="#rid8">8-10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – Children with adverse cytogenetic features account for approximately 15 percent of pediatric AML [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Patients with high-risk cytogenetic features include those that harbor any of the following cytogenetic abnormalities (and lack any of the favorable features described above) [<a href="#rid3">3,11-13</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monosomy 7 </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monosomy 5 or del(5q) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormalities of 3q: inv(3)(q21q26.2) and t(3;3)(q21;q26.2); <em>RPN1::EVI1</em> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(6;9)(p23;q34)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complex karyotype (≥3 cytogenetic abnormalities) </p><p></p><p class="bulletIndent1">Children and adolescents harboring these unfavorable features have &lt;50 percent long-term OS; some features are associated with &lt;20 percent OS [<a href="#rid3">3</a>]. Trisomies are common events in pediatric AML (often involving chromosome 8, 19, or 21) and can occur alone or in conjunction with other karyotypic abnormalities.</p><p></p><p>Cytogenetic abnormalities associated with AML are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities"</a>.)</p><p class="headingAnchor" id="H449859928"><span class="h2">Molecular features</span><span class="headingEndMark"> — </span>Certain mutations are predictive of relapse and associated with prognosis in pediatric AML. </p><p>Mutation testing is an essential component of the diagnostic/classification workup and subsequent risk stratification. Next generation sequencing (NGS) and other emerging technologies can detect cryptic fusion genes, copy number alternations (focal gains or losses of genomic regions), loss of heterozygosity, and AML subtypes [<a href="#rid14">14-16</a>]. </p><p>Molecular features that are associated with prognosis in pediatric AML include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>CEBPA</em></strong> – Mutations involving <em>CEBPA</em> occur in approximately 5 percent of pediatric AML. Children with <em>CEBPA</em> mutations affecting the bZip domain have a more favorable prognosis, with approximately 70 percent long-term OS following treatment with chemotherapy alone [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>NPM1</em></strong> – Mutations involving <em>NPM1</em> are present in approximately 8 to 10 percent of pediatric AML [<a href="#rid19">19</a>]. Only cases of AML with mutated <em>NPM1</em> <strong>without</strong> associated <em>FLT3</em>-ITD (internal tandem repeat) are associated with a favorable prognosis; in such patients, long-term OS is approximately 70 percent with chemotherapy alone. (See  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4502.html" rel="external">"Acute myeloid leukemia: Molecular genetics", section on 'NPM1 mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>FLT3 </em></strong><strong>mutation </strong>– Activating mutations in the <em>FLT3 </em>gene are among the most common recurring somatic mutations in AML. Of these, <em>FLT3</em>-ITD is the most common, and it occurs in 10 to 15 percent of pediatric AML [<a href="#rid20">20,21</a>]. The prevalence of <em>FLT3</em>-ITD increases with age, occurring in 15 to 25 percent of adolescents and young adults. Point mutations of <em>FLT3</em> (ie, activating loop mutations) occur in 5 to 7 percent of childhood AML and have no clear prognostic impact [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/4502.html" rel="external">"Acute myeloid leukemia: Molecular genetics", section on 'FLT3'</a>.)</p><p></p><p class="bulletIndent2">Patients with mutations involving <em>FLT3</em>-ITD with a high allelic ratio (HAR; of mutant to wild-type <em>FLT3</em>) have a poor prognosis. Cooperative groups use different thresholds, but it is generally accepted that an allelic ratio greater than 0.4 to 0.5 is a marker of poor prognosis [<a href="#rid22">22,23</a>]. Patients with HAR <em>FLT3</em>-ITD are more likely to be refractory to induction chemotherapy and are at a greater risk for relapse [<a href="#rid20">20</a>]. Children with HAR <em>FLT3</em>-ITD mutations have a 20 to 30 percent OS with contemporary chemotherapy regimens alone, but the OS is 50 to 60 percent when FLT3 inhibitors and/or consolidation allogeneic hematopoietic cell transplantation (HCT) are employed [<a href="#rid22">22,23</a>]. (See <a class="local">'Postremission management'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>KMT2A</em></strong><strong> rearrangements</strong> – Translocations involving <em>KMT2A</em> (previously called <em>MLL</em>) at the 11q23 locus are present in 15 to 20 percent of pediatric AML cases. Rearrangements involving <em>KMT2A</em> are most prevalent in young children, especially those &lt;2 years [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent2">There are many fusion partners of<em> KMT2A</em>, and prognosis may vary according to the fusion partner. Chromosomal rearrangements, including t(6;11)(q27;q23), t(10;11)(p11.2;q23.3), t(10;11)(p12;q23.3), and t(11;19)(q23;p13.3) have been associated with a poor prognosis [<a href="#rid13">13,25</a>].</p><p></p><p class="bulletIndent2">The most common rearrangement in pediatric AML involving <em>KMT2A</em> is t(9;11)(p22;q23), which accounts for one-half of cases with <em>KMT2A</em> abnormalities, but it is not associated with adverse outcomes [<a href="#rid25">25</a>]. The t(1;11)(q21;23) rearrangement has been associated with a more favorable outcome relative to other <em>KMT2A</em> fusions [<a href="#rid13">13,25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>NUP</em></strong><strong> abnormalities</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>t(6;9)(p23;q34)/<em>DEK::NUP214</em>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><em>NUP98</em> fusions – <em>NUP98::NSD1</em> fusions, which commonly occur with <em>FLT3</em>-ITD mutations, are associated with a poor prognosis in children and adults [<a href="#rid13">13,26-28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>CBFA2T3A::GLIS2</em></strong></p><p></p><p>Other recurring mutations have been identified in pediatric AML (eg, <em>WT1</em>,<em> KIT</em>,<em> NRAS</em>, and<em> KRAS</em>), but prognostic significance has not been confirmed. Their association of these mutations with additional cytogenetic and molecular aberrations suggests they may serve as cooperating mutations in leukemogenesis [<a href="#rid29">29-32</a>]. (See  <a class="medical medical_review" href="/d/html/4502.html" rel="external">"Acute myeloid leukemia: Molecular genetics", section on 'Gene mutations'</a> and  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p class="headingAnchor" id="H449859956"><span class="h2">Treatment response</span><span class="headingEndMark"> — </span>Children with AML that does not harbor prognostically significant cytogenetic or molecular abnormalities are classified as intermediate risk. For these patients, the most important prognostic factor is the response to induction therapy, including the assessment of measurable residual disease (MRD) [<a href="#rid33">33-35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurable residual disease negative</strong> – Children with intermediate-risk AML with negative MRD (eg, &lt;0.1 percent by flow cytometry) experience approximately 65 percent RFS [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurable residual disease positive</strong> – Children with detectable MRD following induction have an inferior prognosis, with approximately 60 percent RFS [<a href="#rid34">34</a>].</p><p></p><p>The prognostic significance of persistent MRD for children with favorable or unfavorable cytogenetic or molecular features is less certain [<a href="#rid34">34,36</a>]. </p><p>Detection of MRD by the expression of leukemia-associated genes or disease-specific mutations is not routinely used but can provide sensitive detection of a low level of residual leukemia and may inform prognostic and therapeutic decisions [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Remission criteria'</a>.)</p><p class="headingAnchor" id="H1940718060"><span class="h1">RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Risk in cases of pediatric AML is based on prognostic factors, including cytogenetic/molecular features and/or response to induction chemotherapy, as described above. (See <a class="local">'Prognostic factors'</a> above.)</p><p>There is general agreement about what constitutes low-risk genetic features in pediatric AML. However, cooperative groups assign cases to high-risk disease using different genetic features and/or definitions for treatment response.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(8;21)(q22;q22); <em>RUNX1::RUNX1T1</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB::MYH11</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated <em>NPM1</em> without <em>FLT3</em>-ITD (internal tandem duplication; normal karyotype)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutated bZip <em>CEBPA</em> (normal karyotype)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate</strong> – Cases that do not harbor cytogenetic or molecular abnormalities that classify them as favorable or adverse risk are categorized as intermediate risk. </p><p></p><p class="bulletIndent1">For cases of intermediate risk, prognosis is primarily driven by response to induction therapy. (See <a class="local">'Treatment response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytogenetic features</strong> (see <a class="local">'Cytogenetics'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>t(6;9)(p23;q34)/<em>DEK::NUP214</em></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Abnormalities of 3q</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monosomy 5 or del(5q)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monosomy 7</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complex karyotype</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Molecular features </strong>(see <a class="local">'Molecular features'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><em>FLT3</em>-ITD</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><em>NUP98</em> fusions</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Certain <em>KMT2A</em> rearrangements </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><em>CBFA2T3A::GLIS2</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – RAM immunophenotype (CD56 high, dim or negative CD45 and CD38, and negative HLA-DR expression) [<a href="#rid15">15</a>]</p><p></p><p class="headingAnchor" id="H449859963"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Children and adolescents with AML should be treated in the context of a current clinical protocol, whenever possible. When that is not possible, treatment should adhere to a contemporary pediatric AML protocol in consultation with experts in the management of pediatric leukemia.</p><p>Our approach to the treatment of pediatric AML is consistent with recommendations from international expert panels [<a href="#rid39">39-41</a>]. </p><p>Information and instructions for referring a patient to an appropriate research center can be obtained from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=13935" target="_blank">United States National Institutes of Health</a>.</p><p class="headingAnchor" id="H449859970"><span class="h2">Induction therapy</span><span class="headingEndMark"> — </span>Induction therapy with an anthracycline (or <a class="drug drug_pediatric" data-topicid="12617" href="/d/drug information/12617.html" rel="external">mitoxantrone</a>) plus <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> is standard therapy in children and adolescents with AML. The doses and schedule of administration and the decision to add a third agent should be guided by the chosen protocol. </p><p>Induction therapy is intensive chemotherapy that seeks to achieve a complete remission (CR). Although achieving CR represents the reduction of the leukemic burden by orders of magnitude, it is generally not sufficient to cure AML in children and adolescents. For most patients, the achievement of CR is followed by consolidation therapy, as described below. (See <a class="local">'Postremission management'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Standard induction chemotherapy comprises an anthracycline (eg, <a class="drug drug_pediatric" data-topicid="13207" href="/d/drug information/13207.html" rel="external">daunorubicin</a>, <a class="drug drug_pediatric" data-topicid="13372" href="/d/drug information/13372.html" rel="external">idarubicin</a>) or <a class="drug drug_pediatric" data-topicid="12617" href="/d/drug information/12617.html" rel="external">mitoxantrone</a> plus extended exposure to <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a>. This generally involves two courses of induction chemotherapy. In some protocols, a third drug is included in induction therapy; examples of third agents include <a class="drug drug_pediatric" data-topicid="13292" href="/d/drug information/13292.html" rel="external">etoposide</a>, 6-thioguanine, <a class="drug drug_pediatric" data-topicid="13174" href="/d/drug information/13174.html" rel="external">gemtuzumab ozogamicin</a> (CD33-directed immunoconjugate), or a kinase inhibitor.</p><p></p><p class="bulletIndent1">For patients with <em>FLT3</em>-ITD (internal tandem repeat) or other <em>FLT3</em> mutations, a kinase inhibitor, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, may be added to induction therapy [<a href="#rid42">42,43</a>]. <a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">Midostaurin</a>, sorafenib, <a class="drug drug_general" data-topicid="142055" href="/d/drug information/142055.html" rel="external">quizartinib</a>, and <a class="drug drug_general" data-topicid="119861" href="/d/drug information/119861.html" rel="external">gilteritinib</a> are approved by the US Food and Drug Administration (FDA) for the treatment of adults with <em>FLT3</em>-mutated AML. Although various kinase inhibitors are undergoing evaluation in children, none is currently approved for treatment in children. Treatment with a kinase inhibitor is typically continued through postremission management. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Toxicity of induction therapy is substantial. Prolonged and profound cytopenias are experienced by all patients and may be complicated by infections from neutropenia, bleeding from thrombocytopenia, and anemia that requires transfusion support.</p><p></p><p class="bulletIndent1">Monitoring of the child during induction therapy and supportive/adjunctive care for treatment-related adverse effects (AEs) are discussed below. (See <a class="local">'Adjunctive/supportive care'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response assessment</strong> – Bone marrow examination is repeated as blood counts recover (typically ≥4 weeks) to assess treatment response and detection of measurable residual disease (MRD).</p><p></p><p class="bulletIndent1">Remission criteria and response to therapy are described separately. (See  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Remission status'</a>.)</p><p></p><p class="bulletIndent1">Patients with CR proceed to postremission management, as described below. (See <a class="local">'Postremission management'</a> below.)</p><p></p><p class="bulletIndent1">Patients who do not achieve CR are managed as refractory AML. (See <a class="local">'Relapsed/refractory AML'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Most contemporary pediatric AML induction regimens are associated with CR in approximately three-quarters of children and adolescents, but the rate may be affected by cytogenetic and molecular features. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthracycline</strong> – No specific anthracycline/anthracenedione is clearly superior in this setting [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="13207" href="/d/drug information/13207.html" rel="external">Daunorubicin</a>, <a class="drug drug_pediatric" data-topicid="13372" href="/d/drug information/13372.html" rel="external">idarubicin</a>, and <a class="drug drug_pediatric" data-topicid="12617" href="/d/drug information/12617.html" rel="external">mitoxantrone</a> have been used for induction therapy for pediatric AML. No specific agent has emerged as clearly superior, based on studies by the Berlin-Frankfurt-Munster (BFM) group, Medical Research Council (MRC), EORTC (European Organisation for Research and Treatment of Cancer), and LAME (Leucemie Aique Myeloide Enfant) [<a href="#rid8">8,45-47</a>]. </p><p></p><p class="bulletIndent2">Children are generally at greater risk for anthracycline-induced cardiotoxicity than adults [<a href="#rid48">48</a>], but the risk of cardiac toxicity at increasing cumulative doses of anthracyclines in children is not well defined.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytarabine</strong> – No specific <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> regimen is proven superior in children.</p><p></p><p class="bulletIndent2">Studies that used various <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> regimens have provided mixed results [<a href="#rid49">49-51</a>], but it is not possible to draw a firm conclusion about the benefit of high-dose versus low-dose cytarabine because of other protocol differences. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Third agent</strong> – There is no conclusive evidence of a survival benefit from the addition of a third agent to induction therapy for pediatric AML.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A trial that randomly assigned 149 children (1 to 18 years) to two cycles of <a class="drug drug_pediatric" data-topicid="13207" href="/d/drug information/13207.html" rel="external">daunorubicin</a> plus <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a>, with or without <a class="drug drug_pediatric" data-topicid="13292" href="/d/drug information/13292.html" rel="external">etoposide</a>, reported no difference in five-year overall survival (OS), five-year event-free survival, or toxicity [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a phase 3 trial for pediatric AML, the addition of <a class="drug drug_pediatric" data-topicid="13174" href="/d/drug information/13174.html" rel="external">gemtuzumab ozogamicin</a> was associated with a lower rate of relapse, but there was no difference in OS compared with chemotherapy only [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent3"><a class="drug drug_pediatric" data-topicid="13174" href="/d/drug information/13174.html" rel="external">Gemtuzumab ozogamicin</a> is approved by the FDA for the treatment of newly diagnosed AML in children.</p><p></p><p class="headingAnchor" id="H3120623220"><span class="h2">Central nervous system management</span><span class="headingEndMark"> — </span>For all children and adolescents with AML, we suggest the administration of intrathecal (IT) chemotherapy as either prophylaxis or treatment based on neurologic evaluation that includes an initial diagnostic lumbar puncture (LP). Central nervous system (CNS)-directed therapy is generally continued through postremission management.</p><p>All patients should undergo an initial diagnostic LP to identify leukemic involvement of the CNS. It is acceptable to delay the initial LP for several days after initiation of therapy to reduce potential leukemic contamination of the CNS and to lessen the risk of bleeding, especially in patients with a coagulopathy at diagnosis. Children with unexplained neurologic abnormalities should also undergo imaging, as discussed above. (See <a class="local">'Clinical/laboratory testing'</a> above.) </p><p>CNS involvement is defined by cytologic confirmation of leukemia cells in the cerebrospinal fluid, clinical signs of CNS leukemia (eg, facial nerve palsy, brain/eye involvement), or a tumor mass/meningeal involvement detected by imaging. </p><p>All children and adolescents with AML receive CNS-directed therapy, as follows. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis</strong> – Patients with no evidence of CNS involvement receive CNS prophylaxis, but the method varies between protocols. </p><p></p><p class="bulletIndent1">Prophylaxis reduces the risk of CNS relapse. In general, either single-agent IT <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> or triple IT therapy (cytarabine, <a class="drug drug_pediatric" data-topicid="12595" href="/d/drug information/12595.html" rel="external">methotrexate</a>, <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a>) is given. Most regimens provide at least one dose of prophylaxis with each course of therapy, but the optimal number of prophylactic IT treatments is uncertain. </p><p></p><p class="bulletIndent1">When CNS prophylaxis is not used, CNS involvement at relapse may be as high as 20 percent [<a href="#rid1">1</a>] compared with &lt;10 percent of patients who received prophylaxis [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">Cranial radiation therapy (RT) should <strong>not</strong> be used for CNS prophylaxis in children and adolescents because of an increased risk for late AEs, including cognitive deficits, endocrine deficits, and secondary malignancies [<a href="#rid54">54-56</a>], as described below. (See <a class="local">'Late effects'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of central nervous system involvement</strong> – Patients with CNS involvement require augmented CNS-directed therapy, but no studies have defined an optimal method or established a consensus.</p><p></p><p class="bulletIndent1">Management of CNS disease should be guided by the chosen treatment regimen. Most approaches deliver frequent IT chemotherapy combined with intensive systemic chemotherapy (eg, high-dose <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> [HiDAC]) [<a href="#rid57">57,58</a>]. Avoidance of cranial RT should be considered to lessen late AEs.</p><p></p><p class="bulletIndent1">CNS involvement is generally found in 5 to 10 percent of children with AML at diagnosis [<a href="#rid57">57</a>], but some studies have estimated the risk in newly diagnosed pediatric AML to be as high as 30 percent [<a href="#rid59">59</a>]. Risk factors associated with CNS involvement include age &lt;2 years; high white blood cell (WBC) count at presentation; hepatosplenomegaly; and t(8;21), inv(16), or t(16;16) [<a href="#rid57">57,58</a>]. </p><p></p><p class="bulletIndent1">CNS involvement at diagnosis is not an adverse prognostic factor for children with AML, and it is not associated with inferior OS when it is treated with intensified CNS-directed therapy [<a href="#rid57">57</a>]. </p><p></p><p class="headingAnchor" id="H449859977"><span class="h2">Postremission management</span><span class="headingEndMark"> — </span>For patients who achieve CR with induction therapy, postremission management is given to deepen the remission, reduce relapses, and achieve long-term survival and cure.</p><p>Consolidation therapy is the mainstay of postremission care; there is only limited evidence to support a role for maintenance therapy in childhood AML.</p><p class="headingAnchor" id="H2197501043"><span class="h3">Consolidation therapy</span><span class="headingEndMark"> — </span>The choice of consolidation varies with prognostic features and details of the chosen protocol. Risk stratification for children with AML is discussed above. (See <a class="local">'Risk stratification'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable risk</strong> – For children with favorable prognosis AML, we suggest HiDAC-based consolidation chemotherapy rather than allogeneic hematopoietic cell transplantation (HCT), observation, or autologous HCT. </p><p></p><p class="bulletIndent1">At least one-third of children who achieve first CR (CR1) will relapse without consolidation therapy, and there is no proven benefit for autologous HCT. Most experts agree that children with favorable features should receive consolidation chemotherapy rather than HCT in CR1 because transplant-associated AEs outweigh the good prognosis for these children. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate/higher risk</strong> – HiDAC or allogeneic HCT are reasonable options for children with intermediate-risk or high-risk features. </p><p></p><p class="bulletIndent1">There is no consensus about which children should receive consolidation chemotherapy versus allogeneic HCT [<a href="#rid60">60,61</a>]. The choice is guided by prognostic risk factors (ie, genetic features of the blasts and/or response to induction therapy) and is defined by the chosen treatment protocol. The decision to choose allogeneic HCT must weigh the reduced rate of relapse against morbidity and mortality associated with transplantation. </p><p></p><p>No trials have randomly assigned children in CR1 to allogeneic HCT versus HiDAC-based consolidation. Most studies that compared approaches used biological randomization (ie, children who had a matched sibling donor [MSD] received transplantation, while those without an MSD received consolidation chemotherapy). Because of evolving transplantation techniques and different criteria for selecting consolidation therapy, it is difficult to compare outcomes across studies. </p><p>In AML99, 240 children with AML were stratified for postremission management based on age, WBC count at diagnosis, cytogenetics, and treatment response [<a href="#rid62">62</a>]. CR was achieved in 95 percent of children and the five-year OS was 75 percent. Children in CR1 were stratified into low-risk (112 children), intermediate-risk (92 children), and high-risk (23 children) groups. Those with low-risk AML or intermediate-risk AML without an MSD received consolidation chemotherapy, while children with intermediate-risk disease with an MSD and all children with high-risk disease were offered allogeneic HCT. There was no difference in OS for children with intermediate-risk AML who received consolidation chemotherapy versus transplantation. At five years, the OS for low-, intermediate-, and high-risk groups were 86, 72, and 57 percent, respectively.</p><p class="headingAnchor" id="H2231486293"><span class="h4">Consolidation chemotherapy</span><span class="headingEndMark"> — </span>Consolidation chemotherapy is generally based on HiDAC, with or without other agents, but the preferred dose and number of cycles of HiDAC differs between cooperative trial groups.</p><p>In AML99, for children with low-risk and intermediate-risk AML who received consolidation chemotherapy, rates of five-year OS were 86 and 72 percent, respectively [<a href="#rid62">62</a>]. The corresponding rates of five-year disease-free survival (DFS) were 71 and 60 percent. There was no difference in outcomes for children with intermediate-risk disease who received chemotherapy versus transplantation, according to the availability of an MSD. (See <a class="local">'Consolidation therapy'</a> above.)</p><p>Other studies have also shown that HiDAC consolidation therapy is associated with good outcomes for most children with AML [<a href="#rid40">40,63</a>]. </p><p>No benefit was associated with autologous HCT compared with consolidation chemotherapy for children with AML who achieved remission [<a href="#rid64">64-66</a>]. </p><p class="headingAnchor" id="H380915152"><span class="h4">Allogeneic hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Allogeneic HCT is primarily offered for children who have AML with adverse pathologic features or limited treatment response. (See <a class="local">'Risk stratification'</a> above.)</p><p>There is broad support for allogeneic HCT for children with high-risk features and positive MRD after induction, but the benefit in specific genetic subsets of AML is not known. A survival benefit with allogeneic HCT must be balanced against transplantation-related mortality (TRM) and long-term AEs, including graft-versus-host disease (GVHD) [<a href="#rid60">60</a>].</p><p>Some studies suggested that allogeneic HCT in CR1 for patients with high-risk AML was associated with improved outcomes [<a href="#rid45">45,60,67</a>], while others reported no benefit compared with induction therapy alone [<a href="#rid68">68,69</a>]. Historical comparisons of outcomes are difficult because of evolving transplantation techniques and decreasing TRM. </p><p class="bulletIndent1"><span class="glyph">●</span>Several studies indicated that allogeneic HCT in CR1 was associated with improved survival in children with high allelic ratio<em> </em>(HAR) <em>FLT3</em>/ITD [<a href="#rid23">23,70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis reported that allocation to HCT was associated with a reduced risk of relapse and an improved DFS and OS [<a href="#rid72">72</a>]. The graft-versus-leukemia effect is more evident in AML than in acute lymphoblastic leukemia [<a href="#rid73">73</a>].</p><p></p><p>MSDs are a preferred donor source, but matched unrelated donor grafts are currently associated with similar outcomes [<a href="#rid61">61,74</a>]. Donor selection is discussed separately. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H4167487444"><span class="h3">Maintenance therapy</span><span class="headingEndMark"> — </span>We suggest not administering maintenance therapy, based on the absence of a proven benefit.</p><p>Results of studies that evaluated maintenance therapy have been mixed.</p><p class="bulletIndent1"><span class="glyph">●</span>A trial (LAME 89/91) that randomly assigned children to 18 months of maintenance therapy (<a class="drug drug_pediatric" data-topicid="12582" href="/d/drug information/12582.html" rel="external">6-mercaptopurine</a> and subcutaneous <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a>) reported no benefit from maintenance therapy [<a href="#rid75">75</a>]. Maintenance therapy was associated with inferior OS (58 versus 81 percent) and did not reduce relapses. Furthermore, children who did not receive maintenance therapy had a higher likelihood of achieving a second CR than those who received maintenance therapy [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, among 215 children who were randomly assigned to 18 months of maintenance therapy (<a class="drug drug_pediatric" data-topicid="12835" href="/d/drug information/12835.html" rel="external">thioguanine</a>, <a class="drug drug_pediatric" data-topicid="12882" href="/d/drug information/12882.html" rel="external">vincristine</a>, <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a>, <a class="drug drug_pediatric" data-topicid="96691" href="/d/drug information/96691.html" rel="external">azacitidine</a>, and <a class="drug drug_pediatric" data-topicid="13191" href="/d/drug information/13191.html" rel="external">cyclophosphamide</a>) versus no maintenance therapy, there was a trend toward inferior five-year OS in children who received maintenance therapy (46 versus 68 percent) and a lower rate of salvage from relapse if maintenance therapy had been given [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance therapy with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> was associated with improved outcomes for children with HAR <em>FLT3</em>-mutated AML in a phase 1/2 study (AAML1031), but the interpretation of outcomes was confounded by a higher rate of allogeneic HCT in children who received sorafenib [<a href="#rid42">42</a>]. Multivariable analysis that accounted for rates of HCT and favorable co-occurring mutations reported that those who did not receive sorafenib had a higher rate of relapse (hazard ratio [HR] 3.03 [95% CI 1.31-7.04]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance therapy using interleukin 2 failed to show a benefit in DFS [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results from a series of studies by the BFM-AML group, which routinely administered one year of maintenance therapy to children with AML, were not better than results from other groups [<a href="#rid8">8,44,46,62,79,80</a>]. </p><p></p><p class="headingAnchor" id="H1107228998"><span class="h1">ADJUNCTIVE/SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Children and adolescents with AML are at risk for complications of the underlying AML and its treatment. Supportive/adjunctive care is an essential aspect of management.</p><p class="headingAnchor" id="H3474930067"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>The child should be examined at least daily during induction therapy and consolidation therapy for infusion reactions, tumor lysis syndrome (TLS; especially those with high blast counts), nausea/vomiting, mucositis, diarrhea, infections, and other complications of therapy. Careful attention is paid to fluid balance and daily weights, and diuretics may be necessary.</p><p>It is especially important to be vigilant for complications in children. Depending on age and development, children may have a limited ability to describe their symptoms, and clinical findings of infection may be blunted or absent during periods of profound neutropenia. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Monitor blood counts daily until recovery of white blood cell (WBC) count to ≥500/microL and platelet transfusion independence is achieved. The frequency of complete blood counts can then be reduced (eg, to every other day), as clinically appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coagulation</strong> – Prothrombin time and partial thromboplastin time should be monitored at least weekly or more frequently, if clinically indicated. Fibrinogen should be measured early in remission induction because disseminated intravascular coagulation (DIC) can be triggered by chemotherapy. In patients with clinical or laboratory evidence of DIC, serum fibrinogen, fibrin degradation products (FDPs), and/or other tests should be monitored at least daily until DIC has resolved. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistries</strong> – Chemistry profile, including electrolytes, blood urea nitrogen (BUN), creatinine, uric acid, calcium, phosphorus, and liver function tests, including lactate dehydrogenase, should be performed at least daily until the risk of TLS has passed. The frequency of testing can then be adjusted as clinically appropriate. </p><p></p><p class="bulletIndent2">Close monitoring of BUN and creatinine may be required throughout the hospitalization for patients who are receiving nephrotoxic agents, such as certain antibiotics. Elevated serum lysozyme levels may lead to renal tubule damage/dysfunction in patients with monocytic/monoblastic leukemia.</p><p></p><p class="headingAnchor" id="H788706962"><span class="h2">Symptom management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nausea and vomiting</strong> – Effective management of nausea and vomiting enhances patient comfort, improves oral hydration and nutritional status, and can reduce the risk of gastrointestinal (GI) bleeding or a Mallory-Weiss tear from forceful vomiting. Management of severe nausea and vomiting is described separately. (See  <a class="medical medical_review" href="/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucositis</strong> – Induction chemotherapy can damage GI epithelia and cause painful oral mucositis and diarrhea. Pain may also limit the ability to take oral fluids and nutrition, exacerbating fluid imbalances and impaired nutrition. </p><p></p><p class="bulletIndent1">Breakdown of the mucosal barrier predisposes to viral, bacterial, and fungal (mostly <em>Candida albicans</em>) superinfection, particularly as the hematologic nadir is reached. Management of chemotherapy-induced mucositis and diarrhea is presented separately. (See  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy", section on 'Treatment of established mucositis'</a>.) </p><p></p><p class="headingAnchor" id="H2114771961"><span class="h2">Cytopenias</span><span class="headingEndMark"> — </span>Profound and prolonged cytopenias are universal with intensive remission induction therapy, and transfusion of red blood cells (RBCs) and platelets should be provided as needed. Granulocyte colony-stimulating factor (G-CSF; <a class="drug drug_pediatric" data-topicid="13301" href="/d/drug information/13301.html" rel="external">filgrastim</a>) and other myeloid growth factors are not routinely administered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusions</strong> – All patients should receive leukoreduced blood products to decrease febrile nonhemolytic transfusion reactions, alloimmunization, and other complications. Irradiated blood products are required for individuals who may be candidates for hematopoietic cell transplantation (HCT) to prevent transfusion-associated graft-versus-host disease (ta-GVHD). For cytomegalovirus (CMV)-negative patients who are candidates for HCT, blood products should be leukoreduced or from CMV-negative donors.</p><p></p><p class="bulletIndent1">There is no consensus threshold for transfusion of RBCs or platelets. We generally transfuse RBCs when the child has anemia-associated symptoms (eg, profound fatigue, dyspnea) and aim to maintain the hemoglobin ≥7 g/dL, but this may vary with age, symptoms, comorbid conditions, and institutional approach. </p><p></p><p class="bulletIndent1">We transfuse platelets prophylactically for patients with platelet counts &lt;10,000/microL or for overt bleeding (eg, oral purpura). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytokines</strong> – There is no demonstrated role for prophylactic administration of G-CSF or other cytokines in this setting [<a href="#rid81">81-83</a>].</p><p></p><p class="headingAnchor" id="H2918203995"><span class="h2">Infections/fever</span><span class="headingEndMark"> — </span>Bacteremia is a leading cause of morbidity and mortality in children who are treated with intensive chemotherapy for AML. Prevention and effective management of bacterial, viral, and fungal infections is critical for optimizing outcomes in these patients. </p><p>The infectious risks are due, in part, to alterations in mucosal barriers and the prolonged absence of neutrophils. Adolescents and young adults may be at a higher risk for treatment-related toxicity compared with younger children [<a href="#rid84">84,85</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever</strong> – Fever or other infectious findings in a neutropenic child require prompt evaluation and administration of empiric, broad-spectrum parenteral antibiotics. The choice of antibiotics should be tailored to the most likely organisms and institutional drug resistance patterns. </p><p></p><p class="bulletIndent1">Initial evaluation of new or prolonged fevers in the setting of neutropenia should include CT of the chest, abdomen, pelvis, and sinuses [<a href="#rid86">86</a>]. If a patient has additional symptoms that involve extremities or the central nervous system (CNS), appropriate imaging and diagnostic testing, including examination of the cerebrospinal fluid, should be obtained. Among patients with radiographic lung findings suspicious for fungal infection, additional diagnostic testing may include bronchial alveolar lavage or biopsy of suspicious lesions [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1">Management of febrile neutropenia in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial infections</strong> – Viridans group streptococci and gram-negative bacteria are common pathogens in this setting. Viridans group streptococci can cause severe sepsis and viridans streptococcal shock syndrome (SVS), resulting in hemodynamic instability and acute respiratory distress syndrome. The risk of infection with viridans group streptococci is more pronounced in patients treated with high-dose <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> (HiDAC) and in those with prolonged neutropenia [<a href="#rid88">88</a>]. Among children treated for AML, as many as 25 percent develop SVS [<a href="#rid89">89</a>]. Prompt recognition of the potential for SVS is critical as rapid progression can be fatal, and appropriate intravenous antibiotics should be started immediately [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal infections</strong> – Severe fungal infections, including those caused by yeasts (eg, <em>Candida</em> spp) and invasive molds (eg, <em>Aspergillus </em>spp), pose a significant risk throughout AML therapy and for those undergoing allogeneic HCT [<a href="#rid91">91</a>]. New or prolonged fevers in the setting of neutropenia should prompt suspicion of fungal infection, and empiric antifungal therapy should be administered immediately for presumed or documented fungal infections; treatment should not be delayed for the completion of the diagnostic workup [<a href="#rid87">87,92,93</a>]. (See  <a class="medical medical_review" href="/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic antimicrobials</strong> – Antibiotic prophylaxis can reduce the risk of bacteremia during intensive chemotherapy treatment, but there is no consensus for use and/or choice of prophylactic antibiotics, antifungals, and antiviral agents during remission induction therapy. </p><p></p><p class="bulletIndent1">Some institutions administer prophylactic fluoroquinolones and/or antifungals, but the potential benefit varies according to the local flora and results of surveillance cultures and must be weighed against the risk of selecting for drug-resistant organisms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibacterial prophylaxis</strong> – Quinolone prophylaxis has not been shown to reduce severe infectious complications (eg, sepsis) or improve survival; thus, the benefits must be balanced against potential toxicity and institutional resistance patterns to avoid the emergence of antibiotic resistance. </p><p></p><p class="bulletIndent1">A phase 3 trial that evaluated <a class="drug drug_pediatric" data-topicid="12549" href="/d/drug information/12549.html" rel="external">levofloxacin</a> prophylaxis versus no prophylaxis was terminated early based on efficacy of levofloxacin [<a href="#rid81">81</a>]. Among 195 children (age 6 months to 21 years) with AML or relapsed acute lymphoblastic leukemia (ALL) who were receiving two cycles of intensive chemotherapy, levofloxacin reduced bacteremia (21.9 versus 43.4 percent; risk difference, 21.6 percent [95% CI 8.8-34.4 percent]). However, for children with AML, the reduction of bacteremia was modest (23.4 versus 29.7 percent), and there was no benefit in a cohort of children undergoing allogeneic HCT. Levofloxacin was also associated with fewer episodes of fever and neutropenia (71.2 versus 82.1 percent), but there was no difference in severe infections, invasive fungal disease, <em>Clostridioides</em> <em>difficile</em>-associated diarrhea, or musculoskeletal toxic effects between trial arms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal prophylaxis</strong> – Antifungal prophylaxis is effective at reducing invasive fungal infections and should be incorporated into the management of children and adolescents receiving therapy for AML [<a href="#rid83">83,94</a>]. </p><p></p><p class="bulletIndent1">Antifungals used for prophylaxis include <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>, which has activity against <em>Candida</em> spp, [<a href="#rid95">95</a>] and <a class="drug drug_pediatric" data-topicid="12885" href="/d/drug information/12885.html" rel="external">voriconazole</a>, <a class="drug drug_pediatric" data-topicid="12997" href="/d/drug information/12997.html" rel="external">posaconazole</a>, and <a class="drug drug_pediatric" data-topicid="13396" href="/d/drug information/13396.html" rel="external">itraconazole</a>, which have activity against both <em>Candida</em> spp and molds, such as <em>Aspergillus </em>spp<em> </em>[<a href="#rid96">96-99</a>]. The choice of regimen depends upon the most likely pathogen, and prophylaxis regimens vary among centers. </p><p></p><p class="bulletIndent1">Consultation with Infectious Disease specialists should be considered in cases of presumed or documented infections. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other infection prevention measures</strong> – Even though most infections during induction therapy are due to endogenous flora, precautions should be taken to limit exposure to exogenous pathogens.</p><p></p><p class="bulletIndent1">Careful hand hygiene, prohibition against sick visitors, and other precautions are used to limit infections. Most methods to reduce the risk of infection have not been rigorously tested, but they are applied because they are relatively simple and may reduce exposure to potential pathogens.</p><p></p><p class="headingAnchor" id="H1879272242"><span class="h2">Other complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperleukocytosis/leukostasis</strong> – WBC count &gt;100,000/microL (&gt;100 x 10<sup>9</sup>/L) is described as hyperleukocytosis. Although the threshold is arbitrary, there is an increased risk for complications including leukostasis, DIC, and TLS. </p><p></p><p class="bulletIndent1">The risk of morbidity and mortality from these complications is highest at the time of diagnosis and within days of initiating therapy [<a href="#rid100">100</a>]. In pediatric AML, higher WBC counts are more common in patients presenting with <em>FLT3</em>-ITD (internal tandem repeat), <em>MLL</em> rearrangements, myelomonocytic phenotypes, and core-binding factor-associated AML [<a href="#rid22">22,100,101</a>]. Hyperleukocytosis is more common with AML compared with acute lymphoblastic leukemia/lymphoblastic lymphoma (LBL), and complications can occur with lower WBC counts in AML [<a href="#rid102">102</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukostasis</strong> – Hyperleukocytosis may lead to tissue damage from blast infiltration and leukostasis, resulting in hemorrhagic and thromboembolic events. Leukostasis is an oncologic<strong> emergency</strong> and can be life threatening, especially the pulmonary and neurologic complications. </p><p></p><p class="bulletIndent2">The clinical presentation of leukostasis varies according to the affected organs. As an example, lung involvement may manifest as dyspnea, hypoxemia, or respiratory failure, while neurologic involvement may manifest as somnolence, coma, or focal neurologic deficits. </p><p></p><p class="bulletIndent2">The most effective means of reducing the WBC count is prompt diagnosis and initiation of chemotherapy [<a href="#rid103">103,104</a>].<strong> </strong>Leukapheresis or exchange transfusion can lower the WBC count temporarily, but these procedures pose significant risk, are temporary, and can exacerbate thrombocytopenia and the risk of DIC [<a href="#rid105">105</a>]. </p><p></p><p class="bulletIndent2">Diagnosis and management of leukostasis is discussed separately. (See  <a class="medical medical_review" href="/d/html/4522.html" rel="external">"Hyperleukocytosis and leukostasis in hematologic malignancies"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumor lysis syndrome</strong> – Supportive management should include vigorous hydration to reduce the risk of tumor lysis and decrease blood viscosity.</p><p></p><p class="bulletIndent2">TLS may manifest as hyperphosphatemia, hypocalcemia (caused by precipitation of calcium phosphate), hyperuricemia, hyperkalemia, and acute renal failure. Rapid leukemic cell lysis after chemotherapy can cause overproduction and overexcretion of uric acid. Precipitation of uric acid in renal tubules can lead to oliguric or anuric renal failure. Administration of prophylactic medications to prevent complications of TLS (eg, <a class="drug drug_pediatric" data-topicid="13339" href="/d/drug information/13339.html" rel="external">allopurinol</a>, <a class="drug drug_pediatric" data-topicid="12760" href="/d/drug information/12760.html" rel="external">rasburicase</a>) and careful monitoring of renal function is essential. (See  <a class="medical medical_review" href="/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disseminated intravascular coagulation</strong> – Acute DIC occurs most commonly in patients presenting with acute promyelocytic leukemia (APL), but it may also occur with AML with monoblastic differentiation or other subtypes.</p><p></p><p class="bulletIndent2">If APL is suspected, <a class="drug drug_pediatric" data-topicid="13099" href="/d/drug information/13099.html" rel="external">all-trans retinoic acid</a> should be started immediately (ie, even before confirmation of the diagnosis of APL). Supportive care of patients with AML-associated DIC should include standard management with appropriate blood products (eg, platelets and coagulation factors), which is essential to minimize bleeding risk. (See  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.) </p><p></p><p class="headingAnchor" id="H2877191561"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2345585989"><span class="h2">Down syndrome and AML</span><span class="headingEndMark"> — </span>Children with Down syndrome (DS; trisomy 21) have a 10 to 20 times greater risk of developing AML compared with children without DS. </p><p>Children with myeloid leukemia associated with DS (ML-DS) <strong>cannot</strong> tolerate the toxic effects of the intensive pediatric AML regimens and must receive distinctive treatment that should be given in a center with specialized expertise. Children with DS have high rates of infection and cardiotoxicity as complications of intensive chemotherapy [<a href="#rid106">106,107</a>]. </p><p>Children with DS also have specific myeloid cell disorders that must be distinguished from AML:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient abnormal myelopoiesis</strong> – Approximately 10 percent of infants with DS (or trisomy 21) manifest transient abnormal myelopoiesis (TAM), which presents with peripheral leukocytosis and circulating cells that resemble megakaryoblasts. Complications of TAM include pericardial and pleural effusions, coagulopathy, hydrops fetalis, hepatic dysfunction, and hepatic fibrosis [<a href="#rid108">108-110</a>]. </p><p></p><p class="bulletIndent1">In most affected children, TAM resolves spontaneously without any treatment [<a href="#rid110">110</a>]. Approximately one-quarter of infants with TAM require chemotherapy to ameliorate respiratory compromise, liver dysfunction, or hyperviscosity associated with hyperleukocytosis [<a href="#rid110">110</a>]. Diagnosis, management, and monitoring of infants with TAM are discussed separately. (See  <a class="medical medical_review" href="/d/html/16914.html" rel="external">"Transient abnormal myelopoiesis (TAM) of Down syndrome (DS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloid leukemia of Down syndrome</strong> – Some children with DS later develop ML-DS, which resembles acute megakaryoblastic leukemia. ML-DS has a good prognosis, unique biologic characteristics (eg, trisomy 21 plus mutated <em>GATA1</em>), and requires distinctive treatment that should be administered in a center with specialized expertise.</p><p></p><p class="bulletIndent1">Children with ML-DS have superior outcomes compared with children without DS who develop AML. ML-DS blasts are extremely sensitive to <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> and <a class="drug drug_pediatric" data-topicid="13207" href="/d/drug information/13207.html" rel="external">daunorubicin</a> [<a href="#rid111">111,112</a>], and children with DS-AML can experience excellent outcomes without the intensive therapy that is used to cure pediatric AML in other children [<a href="#rid113">113-117</a>]. </p><p></p><p class="bulletIndent1">Diagnosis and management of ML-DS is discussed separately. (See  <a class="medical medical_review" href="/d/html/139448.html" rel="external">"Myeloid leukemia associated with Down syndrome (ML-DS)"</a>.)</p><p></p><p class="headingAnchor" id="H1855302182"><span class="h2">Myeloid sarcoma</span><span class="headingEndMark"> — </span>Myeloid sarcoma (chloroma) refers to deposits of myeloid blasts outside the bone marrow that may cause destruction or compression in normal tissue. Management of myeloid sarcoma is like that for other cases of AML.</p><p>Myeloid sarcoma most often affects the central nervous system (CNS), skin, orbit, and bone. The incidence of myeloid sarcoma in pediatric AML is approximately 10 percent and is more common in patients with the following features [<a href="#rid118">118,119</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age</p><p class="bulletIndent1"><span class="glyph">●</span>High white blood cell (WBC) count at diagnosis</p><p class="bulletIndent1"><span class="glyph">●</span>t(8;21)</p><p class="bulletIndent1"><span class="glyph">●</span>Myelomonocytic morphology</p><p></p><p>In children, the prognostic impact of myeloid sarcoma appears to depend upon the site of involvement [<a href="#rid57">57,118,119</a>]. Children with myeloid sarcoma involving the CNS or orbit have improved outcomes compared with those without CNS/orbit involvement and compared with patients without chloroma. By contrast, children with chloromatous skin involvement have higher rates of relapse. </p><p>Extramedullary relapses are more common among children with extramedullary disease at diagnosis. Focal radiation may provide symptomatic benefit, but it does not appear to offer any additional survival benefit compared with chemotherapy in patients with myeloid sarcoma [<a href="#rid118">118,120</a>].</p><p class="headingAnchor" id="H2922287309"><span class="h2">Acute promyelocytic leukemia</span><span class="headingEndMark"> — </span>Acute promyelocytic leukemia (APL) is a rare subtype of AML that is characterized by maturation arrest at the promyelocyte stage, t(15;17)(q22;q21) chromosomal translocation, and <em>PML::RARA</em> rearrangement. Rare cases are associated with other genetic rearrangements. </p><p>Many patients with APL present with disseminated intravascular coagulation (DIC), which requires urgent and aggressive management. <a class="drug drug_pediatric" data-topicid="13099" href="/d/drug information/13099.html" rel="external">All-trans retinoic acid</a> should be started quickly when APL is suspected [<a href="#rid121">121</a>].</p><p>Treatment of APL is risk stratified based on the presenting WBC count [<a href="#rid122">122</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard risk</strong> – WBC &lt;10 x 10<sup>9</sup>/L (&lt;10,000/microL) at presentation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – WBC ≥10 x 10<sup>9</sup>/L </p><p></p><p>Patients with a high WBC count at presentation experience higher rates of relapse and are especially susceptible to early mortality due to DIC.</p><p><a class="drug drug_pediatric" data-topicid="13099" href="/d/drug information/13099.html" rel="external">All-trans retinoic acid</a>, which targets the PML::RARA fusion protein and induces differentiation of APL blasts, is a critical component of APL management [<a href="#rid123">123</a>]. Treatment using an anthracycline, all-trans retinoic acid, and <a class="drug drug_pediatric" data-topicid="16769" href="/d/drug information/16769.html" rel="external">arsenic trioxide</a> is associated with excellent outcomes [<a href="#rid124">124-127</a>]. A prospective study reported that for children with standard-risk APL who were treated with all-trans retinoic acid and arsenic trioxide, outcomes were similar to those using chemotherapy-containing regimens [<a href="#rid128">128</a>]. Patients with high-risk APL treated with an anthracycline, all-trans retinoic acid, and arsenic trioxide for induction therapy, followed by consolidation therapy using all-trans retinoic acid and arsenic trioxide, had outcomes comparable with regimens that used more anthracycline and other conventional chemotherapies. </p><p>Management of APL in children is like that in adults, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p class="headingAnchor" id="H3347035197"><span class="h1">LATE EFFECTS</span><span class="headingEndMark"> — </span>Potential late treatment-related adverse effects include late onset cardiotoxicity, central nervous system (CNS) impairment, decreased linear growth, infertility, cataracts, secondary cancers, and impaired health status due to such factors as neurocognitive dysfunction, depression, fatigue, and anxiety. (See  <a class="medical medical_review" href="/d/html/17020.html" rel="external">"Assuring quality of care for cancer survivors: The survivorship care plan"</a> and  <a class="medical medical_review" href="/d/html/17015.html" rel="external">"Overview of cancer survivorship in adolescents and young adults"</a>.)</p><p>The occurrence of specific complications depends on the patient's age and the type and intensity of therapy with which they were treated. Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=13935" target="_blank">Children's Oncology Group</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Anthracyclines carry a risk of both early and late onset cardiotoxicity, which in severe cases results in heart failure. The cumulative anthracycline dose is the most important risk factor for late cardiac effects. </p><p></p><p class="bulletIndent1">Late cardiac effects are seen in 3 to 5 percent of patients who receive 300 to 440 mg/m<sup>2</sup> cumulative anthracycline dosing with contemporary treatment protocols for pediatric AML [<a href="#rid129">129,130</a>]. There is no dose that is recognized to be safe, but cumulative doses of &gt;300 mg/m<sup>2</sup> are associated with higher rates of late cardiac compromise; this risk rises even more steeply with &gt;400 mg/m<sup>2 </sup>[<a href="#rid131">131,132</a>].</p><p></p><p class="bulletIndent1">Children and adolescents treated for AML should receive long-term follow-up with routine cardiac monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second cancers</strong> – Survivors of childhood AML are at risk for secondary neoplasms, mainly solid tumors.</p><p></p><p class="bulletIndent1">Long-term follow-up data report a prevalence of approximately 1.7 percent [<a href="#rid133">133</a>]. This risk is increased in patients who receive radiation, which may be used in hematopoietic cell transplantation (HCT) conditioning [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine</strong> – The intensity of therapy for AML, especially radiation therapy for HCT, puts survivors at risk for thyroid, gonadal, and other endocrine dysfunction [<a href="#rid133">133-135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Children who receive total body irradiation or cranial irradiation are at risk for growth defects and neurocognitive dysfunction; this is more pronounced in very young children who receive radiation [<a href="#rid136">136</a>].</p><p></p><p>Further details of late effects of treatment of pediatric leukemia are described separately. (See  <a class="medical medical_review" href="/d/html/6247.html" rel="external">"Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents"</a>.) </p><p class="headingAnchor" id="H449860045"><span class="h1">RELAPSED/REFRACTORY AML</span><span class="headingEndMark"> — </span>Approximately one-third of children with AML experience relapse. The prognosis for these children is generally poor and is especially grave for those patients with high-risk disease features or who previously received allogeneic hematopoietic cell transplantation (HCT). </p><p>We strongly encourage enrollment in a clinical trial.</p><p>Time to relapse is an important prognostic factor, with survival &lt;20 percent for patients relapsing within one year of achieving first complete remission (CR) [<a href="#rid137">137</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salvage therapy</strong> – There is no consensus regimen for relapsed or refractory (r/r) pediatric AML. Reinduction regimens vary but commonly include <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a>, with or without an anthracycline. Use of an anthracycline depends on cardiac function at relapse and the cumulative anthracycline dose with initial therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-dose </strong><strong>cytarabine</strong> – Regimens have combined high-dose <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a><strong> </strong>(HiDAC) with other agents, such as <a class="drug drug_pediatric" data-topicid="13305" href="/d/drug information/13305.html" rel="external">fludarabine</a> and <a class="drug drug_pediatric" data-topicid="12924" href="/d/drug information/12924.html" rel="external">clofarabine</a>, and anthracyclines when appropriate [<a href="#rid53">53,138,139</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPX-351</strong> – Treatment of 32 children with CPX-351 (<a class="drug drug_pediatric" data-topicid="131962" href="/d/drug information/131962.html" rel="external">liposomal daunorubicin-cytarabine</a>) was associated with 54 percent CR and 26 percent with CR with incomplete hematologic recovery, most of whom had no detectable measurable residual disease (MRD) by flow cytometry [<a href="#rid140">140</a>]. Treatment was associated with grade ≥3 fever/neutropenia, infection, and rash in 45, 47, and 40 percent, respectively. </p><p></p><p class="bulletIndent2">CPX-351 is approved by the US Food and Drug Administration (FDA) for children ≥1 year with newly diagnosed, therapy-related AML or AML with myelodysplasia-related changes [<a href="#rid141">141-144</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gemtuzumab ozogamicin</strong> – This CD33-directed immunoconjugate has shown responses in relapsed CD33-positive AML [<a href="#rid145">145,146</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="13174" href="/d/drug information/13174.html" rel="external">Gemtuzumab ozogamicin</a> is approved by the FDA for treatment of r/r CD33-positive AML in patients ≥2 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venetoclax</strong> – The BCL-2 inhibitor, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, has activity in children with r/r AML. A study of venetoclax combined with <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> (with or without <a class="drug drug_pediatric" data-topicid="13372" href="/d/drug information/13372.html" rel="external">idarubicin</a>) reported a 70 percent overall response rate, with many patients being MRD negative [<a href="#rid147">147</a>].</p><p></p><p class="bulletIndent1">Achievement of a second CR (CR2) is the most important prognostic factor in long-term survival, and patients who have no evidence of MRD following second-line therapy have the best outcomes [<a href="#rid138">138</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consolidation</strong> – Consolidation with allogeneic HCT is the only approach that offers children with r/r AML who achieve CR2 a chance for long-term survival. </p><p></p><p class="bulletIndent1">Most study groups advocate HCT in CR2 for patients who were not previously transplanted [<a href="#rid53">53,148-150</a>]. Investigational approaches with a clinical trial should be considered for patients who relapse after having previously undergone HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system relapse</strong> – Central nervous system (CNS) relapse can occur either as an isolated relapse or as part of a combined relapse that usually involves the bone marrow. In one study, nearly 10 percent of patients had CNS involvement at relapse [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">CNS relapse is managed as discussed above. (See <a class="local">'Central nervous system management'</a> above.)</p><p></p><p>Other treatments that are under investigation for r/r AML include epigenetic modifiers, targeted inhibitors, monoclonal antibody-based agents, chimeric antigen receptor T cells, novel T cell engagers (eg, dual affinity targeting receptors), and natural killer cell strategies [<a href="#rid151">151-158</a>]. </p><p class="headingAnchor" id="H1722085134"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116628.html" rel="external">"Society guideline links: Acute myeloid leukemia"</a>.)</p><p class="headingAnchor" id="H492190775"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83252.html" rel="external">"Patient education: Leukemia in children (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15790.html" rel="external">"Patient education: Acute myeloid leukemia (AML) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H449860066"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Acute myeloid leukemia (AML) accounts for 15 percent of childhood acute leukemia. Pediatric AML is less common and has an inferior prognosis compared with childhood acute lymphoblastic leukemia (ALL). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Fever, malaise, musculoskeletal pains, lymphadenopathy, hepatosplenomegaly, bleeding, and/or cytopenias are common. Some present with disseminated intravascular coagulation, neurologic abnormalities, hyperleukocytosis, or tumor lysis syndrome. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Clinical, laboratory, and pathologic evaluation is described above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">All children and adolescents should have a lumbar puncture (LP) at diagnosis to assess central nervous system (CNS) involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – AML should be considered in children with unexplained cytopenias or associated symptoms, organomegaly, or circulating blasts. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – Based on morphology and immunophenotype of myeloid blasts in bone marrow, blood, and/or extramedullary sites. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential diagnosis</strong> – ALL and other leukemias and other causes of cytopenias (eg, aplastic anemia) or circulating immature cells should be excluded. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classification</strong> – Classified according to the International Consensus Classification (ICC) or World Health Organization 5<sup>th</sup> edition (WHO5) as a subtype within one of the following large categories (see <a class="local">'Classification'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>AML with defining genetic features</p><p class="bulletIndent3"><span class="glyph">-</span>Other subtypes (defined by ICC and WHO5 criteria)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Informed by cytogenetic/molecular features and treatment response. (See <a class="local">'Prognostic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – Stratified as low, intermediate, or high risk, based on genetic features and initial treatment response. (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Participation in a clinical trial is encouraged. Care should adhere to a contemporary pediatric treatment protocol. Treatment comprises:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – Induction therapy with an anthracycline (or <a class="drug drug_pediatric" data-topicid="12617" href="/d/drug information/12617.html" rel="external">mitoxantrone</a>) plus <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> is standard therapy; choice of agents, protocol for administration, and addition of a third agent is guided by the chosen protocol. (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Central nervous system management</strong> – All patients should have an initial diagnostic LP. (See <a class="local">'Clinical/laboratory testing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No central nervous system disease</strong> – We suggest intrathecal (IT) <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> or triple IT therapy (cytarabine, <a class="drug drug_pediatric" data-topicid="12595" href="/d/drug information/12595.html" rel="external">methotrexate</a>, <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a>) prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Central nervous system management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Central nervous system involvement</strong> – There is no established consensus. Patients are generally treated with more intensive IT and systemic chemotherapy, with or without cranial radiation therapy, as guided by the chosen treatment protocol. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consolidation</strong> – Varies with prognostic features and protocol:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Favorable risk</strong> – We suggest high-dose <a class="drug drug_pediatric" data-topicid="13197" href="/d/drug information/13197.html" rel="external">cytarabine</a> (HiDAC)-based consolidation chemotherapy rather than allogeneic hematopoietic cell transplantation (HCT), observation, or autologous HCT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Consolidation therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intermediate/higher risk</strong> – HiDAC or allogeneic HCT are reasonable options. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance</strong> – We suggest <strong>not</strong> administering maintenance therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive/supportive care</strong> – Monitoring and management of symptoms, cytopenias, and complications are essential aspects of care, as described above. (See <a class="local">'Adjunctive/supportive care'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> – Children with Down syndrome, myeloid sarcoma (chloroma), and acute promyelocytic leukemia require distinctive management. (See <a class="local">'Special populations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late toxicity</strong> – Treatment may be associated with late cardiotoxicity, second cancers, and other late effects. (See <a class="local">'Late effects'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed/refractory AML</strong> – Prognosis of relapsed or refractory AML is poor. There is no consensus for salvage induction therapy. </p><p></p><p class="bulletIndent1">For patients with complete remission after salvage therapy, allogeneic HCT (if eligible) or a clinical trial should be considered. (See <a class="local">'Relapsed/refractory AML'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; :118.</a></li><li><a class="nounderline abstract_t">Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 2018; 24:103.</a></li><li><a class="nounderline abstract_t">Tarlock K, Zhong S, He Y, et al. Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget 2018; 9:26417.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011; 155:366.</a></li><li><a class="nounderline abstract_t">Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol 2014; 32:3021.</a></li><li><a class="nounderline abstract_t">Klein K, Kaspers G, Harrison CJ, et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol 2015; 33:4247.</a></li><li><a class="nounderline abstract_t">Tarlock K, Alonzo TA, Moraleda PP, et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br J Haematol 2014; 166:254.</a></li><li><a class="nounderline abstract_t">Inaba H, Zhou Y, Abla O, et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood 2015; 126:1575.</a></li><li><a class="nounderline abstract_t">Cooper TM, Ries RE, Alonzo TA, et al. Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children’s Oncology Group. Blood 2017; 130:Abstract 407.</a></li><li><a class="nounderline abstract_t">Vujkovic M, Attiyeh EF, Ries RE, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood 2017; 129:3051.</a></li><li><a class="nounderline abstract_t">Eidenschink Brodersen L, Alonzo TA, Menssen AJ, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. Leukemia 2016; 30:2077.</a></li><li><a class="nounderline abstract_t">Gronseth CM, McElhone SE, Storer BE, et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer 2015; 121:2900.</a></li><li><a class="nounderline abstract_t">Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113:6558.</a></li><li><a class="nounderline abstract_t">Tarlock K, Lamble AJ, Wang YC, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. Blood 2021; 138:1137.</a></li><li><a class="nounderline abstract_t">Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110:979.</a></li><li><a class="nounderline abstract_t">Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97:89.</a></li><li><a class="nounderline abstract_t">Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102:2387.</a></li><li><a class="nounderline abstract_t">Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108:3654.</a></li><li><a class="nounderline abstract_t">Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 2014; 124:3441.</a></li><li><a class="nounderline abstract_t">Creutzig U, Büchner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008; 112:562.</a></li><li><a class="nounderline abstract_t">Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011; 25:1239.</a></li><li><a class="nounderline abstract_t">Niktoreh N, Walter C, Zimmermann M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia. J Oncol 2019; 2019:1609128.</a></li><li><a class="nounderline abstract_t">Struski S, Lagarde S, Bories P, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 2017; 31:565.</a></li><li><a class="nounderline abstract_t">Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118:3645.</a></li><li><a class="nounderline abstract_t">Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115:2372.</a></li><li><a class="nounderline abstract_t">Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2010; 116:702.</a></li><li><a class="nounderline abstract_t">Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113:5951.</a></li><li><a class="nounderline abstract_t">Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011; 96:1478.</a></li><li><a class="nounderline abstract_t">van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24:1599.</a></li><li><a class="nounderline abstract_t">Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120:1581.</a></li><li><a class="nounderline abstract_t">Buldini B, Rizzati F, Masetti R, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol 2017; 177:116.</a></li><li><a class="nounderline abstract_t">MRD-AML-BFM Study Group, Langebrake C, Creutzig U, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006; 24:3686.</a></li><li><a class="nounderline abstract_t">Steinbach D, Bader P, Willasch A, et al. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia. Clin Cancer Res 2015; 21:1353.</a></li><li><a class="nounderline abstract_t">Rizzari C, Cazzaniga G, Coliva T, et al. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Expert Rev Anticancer Ther 2011; 11:1391.</a></li><li><a class="nounderline abstract_t">Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012; 120:3187.</a></li><li><a class="nounderline abstract_t">Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19:2130.</a></li><li><a class="nounderline abstract_t">Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol 2008; 26:5797.</a></li><li><a class="nounderline abstract_t">Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol 2022; 40:2023.</a></li><li><a class="nounderline abstract_t">Tarlock K, Chang B, Cooper T, et al. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. Pediatr Blood Cancer 2015; 62:1048.</a></li><li><a class="nounderline abstract_t">Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol 2015; 33:2949.</a></li><li><a class="nounderline abstract_t">Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19:2030.</a></li><li><a class="nounderline abstract_t">Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013; 122:37.</a></li><li><a class="nounderline abstract_t">Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27:5397.</a></li><li><a class="nounderline abstract_t">Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16:e123.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11:543.</a></li><li><a class="nounderline abstract_t">Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19:2101.</a></li><li><a class="nounderline abstract_t">Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011; 118:5409.</a></li><li><a class="nounderline abstract_t">Radhakrishnan V, Bakhshi S, Kayal S, et al. Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. Blood Cancer J 2022; 12:131.</a></li><li><a class="nounderline abstract_t">Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013; 31:599.</a></li><li><a class="nounderline abstract_t">Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 1978; 42:2187.</a></li><li><a class="nounderline abstract_t">Chow EJ, Liu W, Srivastava K, et al. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer 2013; 60:110.</a></li><li><a class="nounderline abstract_t">Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010; 102:881.</a></li><li><a class="nounderline abstract_t">Johnston DL, Alonzo TA, Gerbing RB, et al. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 58:519.</a></li><li><a class="nounderline abstract_t">Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 2003; 17:2090.</a></li><li><a class="nounderline abstract_t">Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19:2025.</a></li><li><a class="nounderline abstract_t">Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116:2205.</a></li><li><a class="nounderline abstract_t">Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol 2014; 166:23.</a></li><li><a class="nounderline abstract_t">Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27:4007.</a></li><li><a class="nounderline abstract_t">Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122:217.</a></li><li><a class="nounderline abstract_t">Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97:56.</a></li><li><a class="nounderline abstract_t">Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334:1428.</a></li><li><a class="nounderline abstract_t">Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007; 13:1.</a></li><li><a class="nounderline abstract_t">Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008; 111:1044.</a></li><li><a class="nounderline abstract_t">Kelly MJ, Horan JT, Alonzo TA, et al. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer 2014; 61:269.</a></li><li><a class="nounderline abstract_t">Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97:21.</a></li><li><a class="nounderline abstract_t">Meshinchi S, Arceci RJ, Sanders JE, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006; 108:400; author reply 400.</a></li><li><a class="nounderline abstract_t">Schechter T, Gassas A, Chen H, et al. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. Biol Blood Marrow Transplant 2015; 21:172.</a></li><li><a class="nounderline abstract_t">Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 2002; 29:843.</a></li><li><a class="nounderline abstract_t">Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120:468.</a></li><li><a class="nounderline abstract_t">Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13:601.</a></li><li><a class="nounderline abstract_t">Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 2005; 19:2082.</a></li><li><a class="nounderline abstract_t">Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21:4377.</a></li><li><a class="nounderline abstract_t">Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol 1994; 12:2367.</a></li><li><a class="nounderline abstract_t">Lange BJ, Yang RK, Gan J, et al. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer 2011; 57:398.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Razzouk BI, Lensing S, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109:157.</a></li><li><a class="nounderline abstract_t">Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2012; 120:978.</a></li><li><a class="nounderline abstract_t">Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 2018; 320:995.</a></li><li><a class="nounderline abstract_t">Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24:4499.</a></li><li><a class="nounderline abstract_t">Lehrnbecher T, Sung L. Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. Expert Rev Hematol 2014; 7:819.</a></li><li><a class="nounderline abstract_t">Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer 2013; 119:4162.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Pounds S, Cao X, et al. Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer 2012; 118:6253.</a></li><li><a class="nounderline abstract_t">Barton CD, Waugh LK, Nielsen MJ, Paulus S. Febrile neutropenia in children treated for malignancy. J Infect 2015; 71 Suppl 1:S27.</a></li><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.</a></li><li><a class="nounderline abstract_t">Feusner JH, Hastings CA. Infections in children with acute myelogenous leukemia. Concepts of management and prevention. J Pediatr Hematol Oncol 1995; 17:234.</a></li><li><a class="nounderline abstract_t">Lewis V, Yanofsky R, Mitchell D, et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Pediatr Infect Dis J 2014; 33:126.</a></li><li><a class="nounderline abstract_t">Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol 2003; 25:696.</a></li><li><a class="nounderline abstract_t">Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22:4384.</a></li><li><a class="nounderline abstract_t">Yamaguchi M, Kurokawa T, Ishiyama K, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol 2011; 90:1209.</a></li><li><a class="nounderline abstract_t">Emiroglu M. Micafungin use in children. Expert Rev Anti Infect Ther 2011; 9:821.</a></li><li><a class="nounderline abstract_t">Fisher BT, Kavcic M, Li Y, et al. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clin Infect Dis 2014; 58:502.</a></li><li><a class="nounderline abstract_t">Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.</a></li><li><a class="nounderline abstract_t">Mehta AK, Langston AA. Use of posaconazole in the treatment of invasive fungal  infections. Expert Rev Hematol 2009; 2:619.</a></li><li><a class="nounderline abstract_t">Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.</a></li><li><a class="nounderline abstract_t">Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis 2012; 55:1515.</a></li><li><a class="nounderline abstract_t">Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21:4615.</a></li><li><a class="nounderline abstract_t">Creutzig U, Ritter J, Budde M, et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987; 60:3071.</a></li><li><a class="nounderline abstract_t">von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28:2682.</a></li><li><a class="nounderline abstract_t">Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3:1590.</a></li><li><a class="nounderline abstract_t">Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26:117.</a></li><li><a class="nounderline abstract_t">Christakopoulos GE, Walker KN, Smith J, et al. Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer 2023; 129:1873.</a></li><li><a class="nounderline abstract_t">Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. Ther Apher 2002; 6:15.</a></li><li><a class="nounderline abstract_t">Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998; 91:608.</a></li><li><a class="nounderline abstract_t">O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008; 26:414.</a></li><li><a class="nounderline abstract_t">Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008; 111:2991.</a></li><li><a class="nounderline abstract_t">Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002; 24:9.</a></li><li><a class="nounderline abstract_t">Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood 2011; 118:6752.</a></li><li><a class="nounderline abstract_t">Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999; 94:1393.</a></li><li><a class="nounderline abstract_t">Ge Y, Jensen TL, Stout ML, et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004; 64:728.</a></li><li><a class="nounderline abstract_t">Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101:130.</a></li><li><a class="nounderline abstract_t">Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80:2210.</a></li><li><a class="nounderline abstract_t">Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19:1355.</a></li><li><a class="nounderline abstract_t">Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128:797.</a></li><li><a class="nounderline abstract_t">Sorrell AD, Alonzo TA, Hilden JM, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 2012; 118:4806.</a></li><li><a class="nounderline abstract_t">Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 2003; 25:760.</a></li><li><a class="nounderline abstract_t">Shimizu H, Saitoh T, Hatsumi N, et al. Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia. Cancer Sci 2012; 103:1513.</a></li><li><a class="nounderline abstract_t">Hall MD, Chen YJ, Schultheiss TE, et al. Treatment outcomes for patients with chloroma receiving radiation therapy. J Med Imaging Radiat Oncol 2014; 58:523.</a></li><li><a class="nounderline abstract_t">Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156:24.</a></li><li><a class="nounderline abstract_t">Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247.</a></li><li><a class="nounderline abstract_t">Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84.</a></li><li><a class="nounderline abstract_t">Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716.</a></li><li><a class="nounderline abstract_t">Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751.</a></li><li><a class="nounderline abstract_t">Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. Br J Haematol 2014; 164:24.</a></li><li><a class="nounderline abstract_t">Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood 2018; 132:405.</a></li><li><a class="nounderline abstract_t">Kutny MA, Alonzo TA, Abla O, et al. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. JAMA Oncol 2022; 8:79.</a></li><li><a class="nounderline abstract_t">Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007; 48:651.</a></li><li><a class="nounderline abstract_t">Getz KD, Sung L, Ky B, et al. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. J Clin Oncol 2019; 37:12.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med 2015; 66:161.</a></li><li><a class="nounderline abstract_t">Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19:191.</a></li><li><a class="nounderline abstract_t">Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer 2008; 112:2071.</a></li><li><a class="nounderline abstract_t">Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27:2356.</a></li><li><a class="nounderline abstract_t">Park J, Choi EK, Kim JH, et al. Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study. Radiat Oncol J 2014; 32:198.</a></li><li><a class="nounderline abstract_t">Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 2010; 17:R141.</a></li><li><a class="nounderline abstract_t">Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24:1422.</a></li><li><a class="nounderline abstract_t">Cooper TM, Alonzo TA, Gerbing RB, et al. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer 2014; 120:2482.</a></li><li><a class="nounderline abstract_t">Fleischhack G, Hasan C, Graf N, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102:647.</a></li><li><a class="nounderline abstract_t">Cooper TM, Absalon MJ, Alonzo TA, et al. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol 2020; 38:2170.</a></li><li class="breakAll">Daunorubicin and cytarabine liposome for injection. United States prescribing information. Revised March 2021. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209401s006lbl.pdf (Accessed on April 21, 2021).</li><li><a class="nounderline abstract_t">Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018; 36:2684.</a></li><li><a class="nounderline abstract_t">Cooper TM, Absalon M, Alonzo TA, et al. AAML1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A report from the Children’s Oncology Group. J Clin Oncol 2019; 37:Abstract 10003.</a></li><li><a class="nounderline abstract_t">Absalon M, O'Brien MM, Phillips CL, et al. A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies. J Clin Oncol 2016; 34:Abstract 10541.</a></li><li><a class="nounderline abstract_t">Niktoreh N, Lerius B, Zimmermann M, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. Haematologica 2019; 104:120.</a></li><li><a class="nounderline abstract_t">Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005; 106:1183.</a></li><li><a class="nounderline abstract_t">Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol 2020; 21:551.</a></li><li><a class="nounderline abstract_t">Kaspers G. How I treat paediatric relapsed acute myeloid leukaemia. Br J Haematol 2014; 166:636.</a></li><li><a class="nounderline abstract_t">Goemans BF, Tamminga RY, Corbijn CM, et al. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica 2008; 93:1418.</a></li><li><a class="nounderline abstract_t">Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106:447.</a></li><li><a class="nounderline abstract_t">Tasian SK, Pollard JA, Aplenc R. Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol 2014; 4:55.</a></li><li><a class="nounderline abstract_t">Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122:1455.</a></li><li><a class="nounderline abstract_t">Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014; 123:356.</a></li><li><a class="nounderline abstract_t">Chichili GR, Huang L, Li H, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med 2015; 7:289ra82.</a></li><li><a class="nounderline abstract_t">He SZ, Busfield S, Ritchie DS, et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 2015; 56:1406.</a></li><li><a class="nounderline abstract_t">Wang QS, Wang Y, Lv HY, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 2015; 23:184.</a></li><li><a class="nounderline abstract_t">Nguyen R, Wu H, Pounds S, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer 2019; 7:81.</a></li><li><a class="nounderline abstract_t">Björklund AT, Carlsten M, Sohlberg E, et al. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clin Cancer Res 2018; 24:1834.</a></li></ol></div><div id="topicVersionRevision">Topic 13935 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561680" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Childhood and adolescent lymphoid and myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29227476" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29899868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3862359" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3862359" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902686" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092781" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573082" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661089" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26215111" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children’s Oncology Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411282" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133823" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26033747" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19304957" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33951732" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440048" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The incidence and clinical significance of nucleophosmin mutations in childhood AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133746" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816873" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912228" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical implications of FLT3 mutations in pediatric AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25270908" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076087" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566656" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31467532" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27694926" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813447" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056794" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413658" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171881" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791472" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668473" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22649108" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240765" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877738" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25501127" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21929313" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879540" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304572" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955460" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35349331" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662999" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304895" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304570" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704089" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826132" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25752563" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451454" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136167" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948298" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36068213" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319696" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/102418" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22628201" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458059" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618422" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523477" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304569" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pediatric acute myeloid leukemia: international progress and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538803" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749666" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A critical review of which children with acute myeloid leukaemia need stem cell procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620491" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846889" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133742" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618581" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222748" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000167" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955900" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21933851" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790584" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139215" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12058234" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517895" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448920" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16121218" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie AiguëMyéloblastique Enfant) Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645428" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964952" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21681921" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Soluble interleukin-2 receptorαactivation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133407" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730539" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30208456" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983120" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359519" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24104395" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22674050" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment outcome in older patients with childhood acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917801" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Febrile neutropenia in children treated for malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620922" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Infections in children with acute myelogenous leukemia. Concepts of management and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064558" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972804" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514380" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21695388" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21905789" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Micafungin use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270167" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064252" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21082953" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Use of posaconazole in the treatment of invasive fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251531" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955439" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673051" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3479232" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439630" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3864942" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22364832" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hyperleukocytosis, leukostasis and leukapheresis: practice management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36943896" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886572" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Leukocytoreduction for acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427716" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202418" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182574" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902751" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849481" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10438727" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744791" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576193" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1384797" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920490" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755283" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Acute leukaemia in children with Down syndrome: a population-based Nordic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22392565" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14528097" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22568487" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24649928" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Treatment outcomes for patients with chloroma receiving radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22050876" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942364" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19468269" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Differentiation therapy of acute myeloid leukemia: past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385856" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705755" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24117210" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : How I treat children and adolescents with acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29789356" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34762093" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17183582" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30379624" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25587648" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Cardiovascular disease in adult survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134212" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18327823" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255307" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25324992" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453080" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Endocrine complications in long-term survivors of childhood cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535146" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771494" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722289" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32401633" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32401633" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30024784" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : AAML1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A report from the Children’s Oncology Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093401" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886328" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171069" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837715" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : How I treat paediatric relapsed acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757852" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677559" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24672775" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Molecular therapeutic approaches for pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23770776" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300852" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26019218" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25248882" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25174587" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30894213" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29444931" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
